New monitor could unlock safer treatment for type 1 diabetes
NCT ID NCT07211802
Summary
This study aims to see if a special monitor that tracks both blood sugar and ketones can reduce the side effects of a drug called sotagliflozin for adults with type 1 diabetes. It will test two different doses of the drug in 52 people who manage their insulin with either daily injections or a pump. The goal is to make this promising treatment safer by using the monitor to catch potential problems early.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES (T1D) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UCSD - Altman Clinical & Translational Research Institute
La Jolla, California, 92037, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.